Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

被引:18
作者
Huang, Jing Li [1 ]
Kizy, Scott [1 ]
Marmor, Schelomo [1 ]
Altman, Ariella [1 ]
Blaes, Anne [2 ]
Beckwith, Heather [2 ]
Tuttle, Todd M. [1 ]
Hui, Jane Yuet Ching [1 ]
机构
[1] Univ Minnesota, Dept Surg, Mayo Mail Code 195,420 Delaware St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA
关键词
Breast cancer; 21-Gene recurrence score; Oncotype DX; Grade; Progesterone receptor; ENDOCRINE THERAPY; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; ASSAY; ESTROGEN; IMPACT; CHEMOTHERAPY; VALIDATION; EQUATIONS;
D O I
10.1007/s10549-018-4955-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization.MethodsWe identified women between the ages of 18 and 74years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS.ResultsWe identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+tumors regardless of age, race, tumor size, and lymph node status.ConclusionsWe found that grade I PR+tumors are associated a<5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
引用
收藏
页码:671 / 677
页数:7
相关论文
共 33 条
  • [21] Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
    Orucevic, Amila
    Bell, John L.
    McNabb, Alison P.
    Heidel, Robert E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (01) : 51 - 61
  • [22] Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis
    Orucevic, Amila
    Heidel, Robert E.
    Bell, John L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (03) : 427 - 435
  • [23] A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Paik, S
    Shak, S
    Tang, G
    Kim, C
    Baker, J
    Cronin, M
    Baehner, FL
    Walker, MG
    Watson, D
    Park, T
    Hiller, W
    Fisher, ER
    Wickerham, DL
    Bryant, J
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) : 2817 - 2826
  • [24] Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Paik, Soonmyung
    Tang, Gong
    Shak, Steven
    Kim, Chungyeul
    Baker, Joffre
    Kim, Wanseop
    Cronin, Maureen
    Baehner, Frederick L.
    Watson, Drew
    Bryant, John
    Costantino, Joseph P.
    Geyer, Charles E., Jr.
    Wickerham, D. Lawrence
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) : 3726 - 3734
  • [25] Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer
    Partin, Jessica F.
    Mamounas, Eleftherios P.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (12) : 3399 - 3406
  • [26] Prognostic significance of Nottingham histologic grade in invasive breast carcinoma
    Rakha, Emad A.
    El-Sayed, Maysa E.
    Lee, Andrew H. S.
    Elston, Christopher W.
    Grainge, Matthew J.
    Hodi, Zsolt
    Blamey, Roger W.
    Ellis, Ian O.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3153 - 3158
  • [27] HISTOLOGICAL GRADING OF BREAST CARCINOMAS - A STUDY OF INTEROBSERVER AGREEMENT
    ROBBINS, P
    PINDER, S
    DEKLERK, N
    DAWKINS, H
    HARVEY, J
    STERRETT, G
    ELLIS, I
    ELSTON, C
    [J]. HUMAN PATHOLOGY, 1995, 26 (08) : 873 - 879
  • [28] Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland
    Smyth, Lillian
    Watson, Geoff
    Walsh, Elaine M.
    Kelly, Catherine M.
    Keane, Maccon
    Kennedy, M. John
    Grogan, Liam
    Hennessy, Bryan T.
    O'Reilly, Seamus
    Coate, Linda E.
    O'Connor, Miriam
    Quinn, Cecily
    Verleger, Katharina
    Schoeman, Olaf
    O'Reilly, Susan
    Walshe, Janice M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) : 573 - 582
  • [29] Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
    Sotiriou, C
    Wirapati, P
    Loi, S
    Harris, A
    Fox, S
    Smeds, J
    Nordgren, H
    Farmer, P
    Praz, V
    Haibe-Kains, B
    Desmedt, C
    Larsimont, D
    Cardoso, F
    Peterse, H
    Nuyten, D
    Buyse, M
    Van de Vijver, MJ
    Bergh, J
    Piccart, MT
    Delorenzi, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (04): : 262 - 272
  • [30] Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
    Sparano, J. A.
    Gray, R. J.
    Makower, D. F.
    Pritchard, K. I.
    Albain, K. S.
    Hayes, D. F.
    Geyer, C. E., Jr.
    Dees, E. C.
    Perez, E. A.
    Olson, J. A., Jr.
    Zujewski, J. A.
    Lively, T.
    Badve, S. S.
    Saphner, T. J.
    Wagner, L. I.
    Whelan, T. J.
    Ellis, M. J.
    Paik, S.
    Wood, W. C.
    Ravdin, P.
    Keane, M. M.
    Gomez Moreno, H. L.
    Reddy, P. S.
    Goggins, T. F.
    Mayer, I. A.
    Brufsky, A. M.
    Toppmeyer, D. L.
    Kaklamani, V. G.
    Atkins, J. N.
    Berenberg, J. L.
    Sledge, G. W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (21) : 2005 - 2014